Fulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on Wednesday

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, analysts expect Fulcrum Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fulcrum Therapeutics Trading Down 0.1%

FULC stock traded down $0.01 on Friday, hitting $7.81. The company had a trading volume of 464,420 shares, compared to its average volume of 562,777. Fulcrum Therapeutics has a 12-month low of $2.32 and a 12-month high of $10.13. The stock's 50-day simple moving average is $7.10 and its 200 day simple moving average is $4.89. The stock has a market cap of $421.58 million, a price-to-earnings ratio of -111.56 and a beta of 2.37.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on FULC shares. Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, May 23rd. Piper Sandler restated an "overweight" rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. Finally, Cantor Fitzgerald upgraded shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 target price on the stock in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $6.29.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Fulcrum Therapeutics stock. Cubist Systematic Strategies LLC purchased a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 57,070 shares of the company's stock, valued at approximately $164,000. Cubist Systematic Strategies LLC owned about 0.11% of Fulcrum Therapeutics at the end of the most recent reporting period. Institutional investors own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.